H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 331 500 KRW -1.63% Market Closed
Market Cap: 4.2T KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Hugel Inc stock under the Base Case scenario is 254 420.81 KRW. Compared to the current market price of 331 500 KRW, Hugel Inc is Overvalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
254 420.81 KRW
Overvaluation 23%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

11.5
P/S
P/S
Price to Sales
11.5
vs History
6
vs Industry
40
Median 3Y
6.3
Median 5Y
8.1
Industry
7.2
Forward
11.1
More Details
37.3
P/E
P/E
Price to Earnings
37.3
vs History
28
vs Industry
5
Median 3Y
25.6
Median 5Y
29.7
Industry
21.4
Forward
29.6
More Details
31.4
P/OCF
P/OCF
Price to OCF
31.4
vs History
7
vs Industry
6
Median 3Y
19.8
Median 5Y
22.3
Industry
20.4
More Details
41.2
P/FCFE
P/FCFE
Price to FCFE
41.2
vs History
57
vs Industry
5
Median 3Y
34.8
Median 5Y
48.3
Industry
24.5
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
0
vs Industry
18
Median 3Y
2.2
Median 5Y
2.7
Industry
2.4
More Details
10.5
EV/S
EV/S
Enterprise Value to Sales
10.5
vs History
1
vs Industry
35
Median 3Y
4.7
Median 5Y
6.3
Industry
7.4
Forward
10
More Details
13.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
13.7
vs History
4
vs Industry
33
Median 3Y
6.1
Median 5Y
8.4
Industry
9.1
More Details
22.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
22.2
vs History
6
vs Industry
7
Median 3Y
11.3
Median 5Y
14.9
Industry
4.1
Forward
20.6
More Details
24.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
24.4
vs History
7
vs Industry
6
Median 3Y
12.7
Median 5Y
16.6
Industry
3.8
Forward
22.5
More Details
28.7
EV/OCF
EV/OCF
Enterprise Value to OCF
28.7
vs History
4
vs Industry
6
Median 3Y
14.6
Median 5Y
17
Industry
5.1
More Details
36.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
36.9
vs History
38
vs Industry
4
Median 3Y
29.3
Median 5Y
33.5
Industry
3.3
More Details
7.9
EV/IC
EV/IC
Enterprise Value to IC
7.9
vs History
0
vs Industry
23
Median 3Y
2.8
Median 5Y
3.9
Industry
4.4
More Details

Multiples Across Competitors

Competitors Multiples
Hugel Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hugel Inc
KOSDAQ:145020
4.2T KRW 11.5 37.3 22.2 24.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 908 785.7 -175 422 -213 018.2 -210 587.4
US
Abbvie Inc
NYSE:ABBV
355.3B USD 6.3 83.8 16.5 24.9
US
Amgen Inc
NASDAQ:AMGN
164.1B USD 4.9 40.1 16.2 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
136.2B USD 4.7 283.6 11.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD 11.7 -240 26.3 27.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 908.7 -487.1 -530.4 -516.3
AU
CSL Ltd
ASX:CSL
122.2B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
70.2B USD 4.9 15.9 10.3 11.5
US
Seagen Inc
F:SGT
39.3B EUR 18.4 -56.4 -60.6 -54.7
NL
argenx SE
XBRU:ARGX
32.6B EUR 16 42 309.4 -2 279.4
P/S Multiple
Revenue Growth P/S to Growth
KR
H
Hugel Inc
KOSDAQ:145020
Average P/S: 3 355 525.3
11.5
19%
0.6
FR
Pharnext SCA
OTC:PNEXF
36 908 785.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 908.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.9
7%
0.7
US
S
Seagen Inc
F:SGT
18.4
30%
0.6
NL
argenx SE
XBRU:ARGX
16
37%
0.4
P/E Multiple
Earnings Growth PEG
KR
H
Hugel Inc
KOSDAQ:145020
Average P/E: 75.8
37.3
34%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -175 422 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.8
88%
1
US
Amgen Inc
NASDAQ:AMGN
40.1
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
283.6
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -487.1 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.4 N/A N/A
NL
argenx SE
XBRU:ARGX
42
19%
2.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
H
Hugel Inc
KOSDAQ:145020
Average EV/EBITDA: 53.7
22.2
31%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 018.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.2
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.1
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.3
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.6 N/A N/A
NL
argenx SE
XBRU:ARGX
309.4
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
H
Hugel Inc
KOSDAQ:145020
Average EV/EBIT: 21.8
24.4
33%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 587.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.9
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 279.4 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.